Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age
Authors:
- Franz SchaeferFSFranz Schaefer
- Rosanna CoppoRCRosanna Coppo
- Arvind BaggaABArvind Bagga
- Prabha SenguttuvanPSPrabha Senguttuvan
- Rolf SchlosshauerRSRolf Schlosshauer
- Ying ZhangYZYing Zhang
- Mahomed KadwaMKMahomed Kadwa
- 1 May 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 31 (5) , 993-1000
Abstract
To evaluate a dose-dependent reduction in blood pressure (BP) and overall safety of valsartan in hypertensive children. In a multicenter, randomized, double-blind, parallel-group study, 75 patients with a documented history of hypertension were randomized (2 : 1 : 2) to receive valsartan (0.25, 1 or 4 mg/kg per day) for 6 weeks, then rerandomized (1 : 1) to receive placebo or valsartan for 2 weeks. This followed the 18-week extension study in which all patients received open-label valsartan (1 mg/kg initial dose, titratable up to 4 mg/kg). The primary endpoint was the slope analysis of the dose-response curve for mean sitting SBP (MSSBP) derived through MSSBP reduction over the first 6 weeks. Safety was assessed in terms of adverse events and serious adverse events (SAEs). At Week 6, significant reductions in MSSBP (P < 0.05) from baseline were observed for all three valsartan doses. Greater reductions were observed with the medium and high doses, although the dose-response trend was not statistically significant (P = 0.099). At Week 8, a greater increase in BP was observed in patients who switched from valsartan to placebo; the difference was not significant. At the extension endpoint, MSSBP was comparable to that observed at Week 6 of the core study. Overall, valsartan was well tolerated with no dose-dependent increase in adverse events during the dose-ranging period (Week 0-6) and a comparable incidence of adverse events to placebo during the placebo withdrawal period (Week 7-8). Although a dose-response trend was observed, statistical significance was not achieved during the dose ranging (primary endpoint) or the placebo-withdrawal periods of the study. However, valsartan demonstrated significant reductions in BP compared with baseline and provided consistent reductions over 26 weeks.Keywords
This publication has 21 references indexed in Scilit:
- Effectiveness and Safety of Valsartan in Children Aged 6 to 16 Years With HypertensionThe Journal of Clinical Hypertension, 2011
- ARBs and ACEis together in the treatment of hypertension and its complications? current practical recommendationsExpert Opinion on Pharmacotherapy, 2010
- Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipineVascular Health and Risk Management, 2010
- Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertensionJournal of Human Hypertension, 2009
- Ambulatory Blood Pressure Monitoring in Children and Adolescents: Recommendations for Standard AssessmentHypertension, 2008
- Efficacy and Safety of the Angiotensin Receptor Blocker Valsartan in Children With Hypertension Aged 1 to 5 YearsHypertension, 2008
- Pediatric Antihypertensive Trial FailuresHypertension, 2008
- Elevated blood pressure and decreased cognitive function among school-age children and adolescents in the United StatesThe Journal of Pediatrics, 2003
- Angiotensin II receptor blockers and cardiovascular outcomes: The evidence now and in the futureJournal of the Renin-Angiotensin-Aldosterone System, 2001
- ValsartanDrugs, 1997